<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Gizem Metin, MD – Curriculum Vitae</title>
  <style>
    :root {
      --primary: #003366; /* navy */
      --accent: #005ea6;
      --grey: #444;
      font-size: 17px;
    }
    body {
      font-family: "Lato", Arial, sans-serif;
      margin: 0;
      color: var(--grey);
      line-height: 1.45;
    }
    header {
      background: var(--primary);
      color: #fff;
      padding: 1.8rem 1rem;
      text-align: center;
    }
    h1 { margin: 0 0 0.3rem; font-size: 2rem; }
    h2 { color: var(--primary); margin-top: 2.2rem; font-size: 1.35rem; border-bottom: 2px solid var(--accent); padding-bottom: 0.2rem; }
    h3 { margin: 0.6rem 0 0.3rem; font-size: 1.05rem; color: var(--accent); }
    section { max-width: 920px; margin: auto; padding: 0 1rem; }
    ul { margin: 0 0 0.8rem 1.2rem; }
    li { margin-bottom: 0.35rem; }
    .two-col { display: grid; grid-template-columns: 2fr 1fr; gap: 1.5rem; }
    .card { margin-bottom: 1.6rem; }
    .tagline { font-size: 1rem; margin-top: 0.2rem; }
    .contact { font-size: 0.95rem; margin-top: 0.4rem; }
    @media (max-width: 800px) {
      .two-col { grid-template-columns: 1fr; }
    }
  </style>
</head>
<body>
  <header>
    <h1>Gizem Metin, MD</h1>
    <div class="tagline">Senior Medical &amp; Clinical Science Professional</div>
    <div class="contact">Skellefteå, Sweden · gizemmetin1@gmail.com · +46&nbsp;702&nbsp;177&nbsp;989 · <a href="https://linkedin.com/in/gizemmetin1" style="color:#fff;text-decoration:underline;">LinkedIn</a></div>
  </header>

  <section>
    <h2>Professional&nbsp;Summary</h2>
    <p>Physician‑scientist with 9&nbsp;years spanning frontline medicine and pharmaceutical R&amp;D / Medical Affairs (oncology, rare disease, immunology). Led evidence generation across 13&nbsp;EMEA markets, pioneered digital RWE methods—including an actigraph‑based 6MWD study—and steered successful launches such as Erleada® (apalutamide). Experienced in Phase&nbsp;II–III oversight (&gt;100&nbsp;sites, 3&nbsp;global trials) and known for cross‑functional leadership.</p>

    <div class="two-col">
      <div>
        <h2>Professional&nbsp;Experience</h2>

        <div class="card">
          <h3>Regional Medical Manager, R&amp;D (EMEA) &nbsp;–&nbsp; Johnson&nbsp;&amp;&nbsp;Johnson Innovative&nbsp;Medicine</h3>
          <em>Remote (Sweden) · Oct&nbsp;2022 – Present</em>
          <ul>
            <li>Field arm of Global Clinical Science, supporting &gt;100&nbsp;active sites in 13&nbsp;countries.</li>
            <li>Maintained audit‑readiness; accelerated first‑patient‑in by &gt;2&nbsp;weeks.</li>
            <li>Oversaw Phase&nbsp;III trials in PAH, CTEPH &amp; paediatric rare disease; hosted 3 investigator meetings toward 900‑patient target.</li>
            <li>Resolved investigator queries within one day, lifting recruitment‑satisfaction scores.</li>
          </ul>
        </div>

        <div class="card">
          <h3>Medical Manager, Pulmonary Arterial Hypertension &nbsp;–&nbsp; J&amp;J Innovative&nbsp;Medicine</h3>
          <em>Istanbul · Nov&nbsp;2021 – Oct&nbsp;2022</em>
          <ul>
            <li>Led strategy for Tracleer®, Opsumit® &amp; Uptravi® across Türkiye, Israel &amp; Balkans.</li>
            <li>Designed actigraph‑based remote 6MWD RWE study; methodology adopted into global protocol Amendment&nbsp;02&nbsp;(2024).</li>
            <li>Drove double‑digit gain in patient identification via guideline‑aligned programmes.</li>
          </ul>
        </div>

        <div class="card">
          <h3>Medical Advisor, Oncology &nbsp;–&nbsp; J&amp;J Innovative&nbsp;Medicine</h3>
          <em>Istanbul · Mar&nbsp;2020 – Oct&nbsp;2021</em>
          <ul>
            <li>Owned Erleada® launch narrative; 12 ad‑boards; achieved double‑digit NHT share in Turkey within 12&nbsp;months.</li>
            <li>Co‑designed 360° launch‑readiness workshop on amivantamab endpoints &amp; accelerated pathways.</li>
            <li>Mapped FGFR testing at 40+ centres; reduced external costs via on‑site labs.</li>
          </ul>
        </div>

        <div class="card">
          <h3>Emergency Medicine Resident &nbsp;–&nbsp; Ministry&nbsp;of&nbsp;Health&nbsp;Türkiye</h3>
          <em>Istanbul · Jun&nbsp;2018 – Feb&nbsp;2020</em>
          <ul>
            <li>Treated ≈26 000 emergency cases; performed critical trauma procedures.</li>
            <li>Presented international case studies; delivered bi‑weekly peer‑training sessions.</li>
          </ul>
        </div>
      </div>

      <div>
        <h2>Core&nbsp;Competencies</h2>
        <ul>
          <li>Med Affairs &amp; Launch Excellence</li>
          <li>RWE &amp; Digital Endpoints</li>
          <li>Clinical Endpoints &amp; 360° Readiness</li>
          <li>Phase&nbsp;II–III Oversight</li>
          <li>KOL / Advisory Board Mgmt</li>
          <li>Competitive Intel &amp; Mature Brands</li>
          <li>EU MDR / GxP Compliance</li>
        </ul>

        <h2>Key&nbsp;Achievements</h2>
        <ul>
          <li>Actigraph‑enabled 6MWD study → protocol Amendment&nbsp;02 (2024).</li>
          <li>Double‑digit NHT share for Erleada® in Turkey (12 months).</li>
          <li>Standardised KOL model; +37 % MSL interactions.</li>
        </ul>

        <h2>Education &amp; Certification</h2>
        <p><strong>MD</strong>, Istanbul University (2017)</p>
        <p>Occupational Physician Certification, Turkish MoLSS (2018)</p>

        <h2>Professional&nbsp;Affiliations</h2>
        <ul>
          <li>Recurring delegate &amp; sponsor – ESMO, ASCO, ESC</li>
          <li>Annual participant – Turkish Cardiology &amp; Urooncology Societies</li>
        </ul>

        <h2>Technical&nbsp;Skills</h2>
        <p>Veeva CRM &amp; Vault (CTMS/QualityDocs) · Salesforce Health Cloud · Medidata Rave · IQVIA · SharePoint · Teams · Notion · Tableau · TriNetX · Power BI · Jira</p>

        <h2>Personal&nbsp;Interests</h2>
        <p>Open‑water Scuba Diving · Smart tech &amp; connected devices · Music history &amp; jazz · Medical humanities &amp; bioethics</p>

        <h2>Availability</h2>
        <p>Two‑month notice · Eligible for Denmark Fast‑Track Scheme salary bracket</p>
      </div>
    </div>
  </section>
</body>
</html>
